Geron Reports Strong RYTELO Revenue Growth and Strategic Shift in Clinical Focus
Geron (GERN) reported strong third-quarter 2026 results, highlighted by a 27% year-over-year increase in net product revenue for its drug RYTELO, reaching $60.1 million. The company expects full-year net revenue to land at the mid-to-high end of its previously issued guidance range of $220 million to $240 million, driven by expanding adoption in community oncology clinics. Strategically, Geron has discontinued its Phase III IMpactMF trial for relapsed myelofibrosis after an independent committee determined it was unlikely to meet primary endpoints. While this ends a specific clinical path, management noted it eliminates 'clinical overhang' and reduces future spending. Additionally, the company plans a capital-efficient launch of RYTELO in Germany by year-end 2026 using a gated distribution model. Financially, Geron is focusing on operational efficiency, having reduced year-to-date operating expenses by 9%. With $339 million in cash reserves and improved expense controls, the company expressed interest in leveraging its liquidity to acquire additional hematology assets.
Tickers: $GERN
Topics: clinical trial discontinuation myelodysplastic syndromes product launch revenue growth
Read the full article at Motley Fool
Part of the story Geron Reports Strong RYTELO Revenue Growth and Strategic Shift in Clinical Focus (2 articles)